Pfizer Inc. (NYSE:PFE) Shares Sold by MetLife Investment Management LLC

MetLife Investment Management LLC trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 2.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,473,575 shares of the biopharmaceutical company's stock after selling 37,969 shares during the quarter. MetLife Investment Management LLC's holdings in Pfizer were worth $42,645,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of PFE. China Universal Asset Management Co. Ltd. acquired a new position in Pfizer in the 1st quarter valued at about $315,000. Kennedy Capital Management LLC acquired a new position in shares of Pfizer in the first quarter valued at approximately $3,992,000. Tidal Investments LLC increased its stake in Pfizer by 6.8% during the 1st quarter. Tidal Investments LLC now owns 317,384 shares of the biopharmaceutical company's stock worth $8,808,000 after buying an additional 20,241 shares during the period. Coppell Advisory Solutions Corp. acquired a new stake in Pfizer during the 1st quarter worth approximately $368,000. Finally, New Covenant Trust Company N.A. purchased a new position in Pfizer in the 1st quarter valued at approximately $220,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on PFE. Cantor Fitzgerald reiterated an "overweight" rating and issued a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. Barclays boosted their price objective on Pfizer from $30.00 to $32.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 31st. Citigroup assumed coverage on shares of Pfizer in a report on Friday, October 25th. They issued a "neutral" rating and a $30.00 target price on the stock. Daiwa Capital Markets raised shares of Pfizer from a "neutral" rating to an "outperform" rating and increased their price objective for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Finally, Evercore ISI raised shares of Pfizer to a "strong-buy" rating in a research report on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $32.92.

Insider Activity

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of the company's stock in a transaction on Wednesday, October 30th. The shares were bought at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the transaction, the director now owns 10,000 shares of the company's stock, valued at approximately $282,400. This trade represents a 11.11 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.06% of the company's stock.

Pfizer Stock Performance

NYSE PFE traded up $0.06 on Wednesday, reaching $25.83. The stock had a trading volume of 28,200,744 shares, compared to its average volume of 38,504,215. The stock has a market cap of $146.38 billion, a P/E ratio of 34.91, a price-to-earnings-growth ratio of 0.83 and a beta of 0.67. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The business's 50-day moving average price is $27.97 and its 200 day moving average price is $28.52. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. During the same period last year, the firm posted ($0.17) EPS. Pfizer's revenue for the quarter was up 31.2% on a year-over-year basis. As a group, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 6.50%. Pfizer's dividend payout ratio (DPR) is currently 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.